JAMA Oncology reports in 1st 10 mos of pandemic, 16,500 cancer pts died from COVID+complications; w/ signific more COVID

Article Drug Safety

Neoplasia and Autoimmune Disease

Jack Cush, MD Apr 27, 2026

Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint inhibitor-induced rheumatic disease).

Article Education/ACR/EULAR

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD Oct 9, 2026

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. FDA has approved rembrutinib (Rhapsido - BTK inhibitor from Novartis)as 1st Rx for…

Article Drug Safety

Don't Hold the Biologic or JAK with COVID-19 Vaccination

Jack Cush, MD Oct 8, 2026

A randomized clinical trial in inflammatory arthritis arthritis shows that temporarily holding biologic or Janus kinase (JAK) inhibitor therapy at the time of COVID-19 vaccination is not warranted.